Urology for Practice, 2009, issue 5

Autodidaktický test 5/09

Urolog. pro Praxi, 2009; 10(5)

Editorial

1 000 transplantácií obličiek na Urologickej klinike v Bratislave

prof. MUDr. Ján Breza DrSc

Urolog. pro Praxi, 2009; 10(5): 255

Review articles

Is it possible to optimize treatment of patients with overactive bladder and erectile dysfunction in the practice ?

MUDr. Libor Zámečník FEBU

Urolog. pro Praxi, 2009; 10(5): 262-263

The author summarizes the knowledge on the co-occurrence of lower urinary tract symptoms/overactive bladder and erectile dysfunction. Based on the literature data, the relationship of these symptoms, their prevalence, and new treatment options using combination therapy with type-5 phosphodiesterase inhibitors are presented.

Hormone replacement therapy of aging men

prof. MUDr. RNDr. Luboslav Stárka DrSc

Urolog. pro Praxi, 2009; 10(5): 264-268

The aim of the study was to review actual problems and recent findings in diagnosis and treatment of male late-onset hypogonadism and guidelines, which appeared recently. Conclusions of present guidelines for testosterone treatment of hypogonadism of aging males and the joint statements of the International society of study of aging male ISSAM, International society of andrology ISA, and European association for Urology EAU for investigation, diagnosis, treatment and monitoring of male late-onset hypogonadism.

Controversy and discrepance of overactive bladder

MUDr. Radovan Vrtal Ph.D

Urolog. pro Praxi, 2009; 10(5): 269-273

Overactive bladder (OAB) is chronical and most exhausting dissease of lower urinary tract. Prevalence is more than 16 % of whole community. In most of cases we don´t be able to detect ethiology of overactive bladder. OAB is defined as a complex of symptoms with their specific signs. To this time it is not known exact etiology and pathophysiology. We can use standardised diagnostics and treatment algorithms. The last valid terminology ICS is from 2002.

Current trends in stress urinary incontinence surgery

MUDr. Daniel Struppl

Urolog. pro Praxi, 2009; 10(5): 274-278

The treatment of stress urinary incontinence in women is very important issue nowadays and the urogynaecology has become one of the most progressive part of the gynaecology as well. The real breakthrough in the surgical therapy was the development of the tension free concept of minimally invasive urethropexy. We summarize the current surgical modalities of these methods and introduce the next development and trends in surgical treatment of stress urinary incontinence (SUI).

Benign prostatic hyperplasia - combination treatment with alpha blockers and 5-alpha-reductase inhibitors

MUDr. Martin Lukeš, MUDr. Jiří Heráček

Urolog. pro Praxi, 2009; 10(5): 279-281

Benign prostatic hyperplasia (BPH) is the most common benign tumour in elderly men. The clinical manifestation of this disease in the form of lower urinary tract symptoms (LUTS) reduces the quality of life of patients. The authors summarize the current options and trends in treating benign prostatic hyperplasia and specify the role of individual drug groups, particularly their possible combinations in treating BPH.

Bisphosphonates in treating bone lesions in urology

MUDr. Michaela Matoušková, doc. MUDr. Miroslav Hanuš CSc

Urolog. pro Praxi, 2009; 10(5): 282-286

High incidence of bone metastatic disease has been typical for many malignant cancers, incl. urological tumors. Thanks to the effect of oncological therapy growing number of patients survive. Bone metastases and its complications remarcably shorten length of the bearers life and lowered their quality of life. Bisphosphonates therapy in cases with bone metastases are, at present, part of complex therapy. Modern therapeutic modalities using the bisphosphonates cytotoxic effect present shisf from only palliative therapy to the curative adjuvant regimens.

Transrectal prostate biopsy in diagnosing prostate cancer

MUDr. Kamil Belej, Ph.D., FEBU

Urolog. pro Praxi, 2009; 10(5): 287-293

Historically, the prostate was evaluated for cancer by simple digital rectal examination, and biopsy to obtain a tissue diagnosis of cancer was performed blindly. The advent of ultrasound technology offered a new way to evaluate the prostate, and biopsy techniques were soon developed to incorporate ultrasound guidance. The article reviews transrectal ultrasound-guided biopsy of the prostate in the diagnosis of prostate cancer. This technique is described as performed according to the current knowledge.

The exstrophy-epispadias complex: a severe congenital anomaly of an uropoetic tract

MUDr. Ivo Novák Ph.D, MUDr. Miloš Broďák Ph.D, prof. MUDr. Hviezdoslav Stefan CSc

Urolog. pro Praxi, 2009; 10(5): 294-296

Congenital urinary tract anomalies are the second most common defects in childhood after congenital heart diseases. An exstrophyepispadias complex is the severe uncommon congenital anomaly of urinary tract. Potential causes and diagnostic of the affection are discussed in the paper. Possibility of treatment, complicationes and asumption disease are disputed in details.

Case report

Liposarcoma of the retroperitoneum

MUDr. Jaroslav Kaňa

Urolog. pro Praxi, 2009; 10(5): 297-298

The author presents a case of a patient with large well diferentiated retroperitoneal liposarcoma. In spite of its whole exstirpation there was a recurrence very early after surgical treatment. This review article summarize diagnostic and therapeutic gudilines of the dissease and its dispensarisation.

Perirenal retroperitoeal fibrosis

MUDr. Michal Fedorko, MUDr. Miroslav Krhovský

Urolog. pro Praxi, 2009; 10(5): 299-301

We present a case of a female patient with a rare perirenal form of idiopathic retroperitoneal fibrosis, describe complicated course of the diseaese, chosen treatment and follow-up within 30 months from initial diagnosis. Despite limited treatment options and unfavourable prognosis expectations, the patient has been in satisfactory condition till now.

For nurses

BCG immunotherapy for bladder cancer

Mgr. Monika Kyselová

Urolog. pro Praxi, 2009; 10(5): 302-304

Bladder cancer is the second-leading urological malignancy. It occurs in virtually all age categories, most commonly around sixty years of age. Bladder tumours may be superficial, infiltrating, or metastatic. Intravesical instillation of BCG vaccine using ImmuCyst is one of the methods used to treat superficial bladder tumours that are recurrent and very likely to progress to invasion (T1G3) and CIS.